Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Laura Sahyoun

IBD · WCM

View

Dr. Uma Mahadevan

IBD · UCSF

View

Dr. Deborah Proctor

IBD · Yale College

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View

Dr. Rushabh Modi

General GI · Kaiser Permanente

View

Dr. Brennan Spiegel

General GI · Cedars-Sinai

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    High Rates of Seroprotection for Measles in Pediatric Patients With Inflammatory Bowel Disease.

    May 20, 2026DOI: 10.14309/ajg.0000000000004050Journal ArticleACG

    Written by: Freddy CalderaMary S HayneyJennifer A StropleArthur J KastlJeremy AdlerMargie BoccieriXian ZhangMillie D LongMichael D Kappelman

    Find these authors on Roon

    FC
    Dr. Freddy Caldera
    IBD · UW

    Summary

    INTRODUCTION: The ongoing US measles outbreak raises concerns for immunosuppressed children with inflammatory bowel disease (IBD).METHODS: We evaluated measles seroprotection in pediatric patients with IBD using a high-sensitivity ELISA (Zeus) compared with a standard commercial assay.RESULTS: Among 176 patients, 173 (98%) were seropositive despite 87% being on immunosuppressive therapy. In comparison, only 163 (93%) were seropositive by commercial assay, resulting in a negative predictive value of 23%.DISCUSSION: Children with IBD have high measles seroprotection. A negative commercial result should not be interpreted as lack of seroprotection, highlighting the need for more accurate assays.
    FCDr. Freddy Caldera

    Dr. Freddy Caldera

    Gastroenterology · Inflammatory Bowel Diseases
    University of Wisconsin–Madison
    freddy